COLL
Price
$34.82
Change
-$0.41 (-1.16%)
Updated
Jul 13 closing price
Capitalization
1.13B
16 days until earnings call
Intraday BUY SELL Signals
ORGO
Price
$2.27
Change
-$0.13 (-5.42%)
Updated
Jul 13 closing price
Capitalization
292.09M
23 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

COLL vs ORGO

COLL vs ORGO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
COLL vs. ORGO commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COLL is a Buy and ORGO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (COLL: $34.82 vs. ORGO: $2.27)
Brand notoriety: COLL and ORGO are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: COLL: 52% vs. ORGO: 68%
Market capitalization -- COLL: $1.13B vs. ORGO: $292.09M
COLL [@Pharmaceuticals: Generic] is valued at $1.13B. ORGO’s [@Pharmaceuticals: Generic] market capitalization is $292.09M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.97B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COLL’s FA Score shows that 0 FA rating(s) are green whileORGO’s FA Score has 0 green FA rating(s).

  • COLL’s FA Score: 0 green, 5 red.
  • ORGO’s FA Score: 0 green, 5 red.
According to our system of comparison, COLL is a better buy in the long-term than ORGO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COLL’s TA Score shows that 5 TA indicator(s) are bullish while ORGO’s TA Score has 3 bullish TA indicator(s).

  • COLL’s TA Score: 5 bullish, 4 bearish.
  • ORGO’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, COLL is a better buy in the short-term than ORGO.

Price Growth

COLL (@Pharmaceuticals: Generic) experienced а -7.07% price change this week, while ORGO (@Pharmaceuticals: Generic) price change was -8.47% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.88%. For the same industry, the average monthly price growth was +0.21%, and the average quarterly price growth was +13.40%.

Reported Earning Dates

COLL is expected to report earnings on Jul 30, 2026.

ORGO is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-3.88% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
COLL($1.13B) has a higher market cap than ORGO($292M). COLL (16.90) and ORGO (16.87) have similar P/E ratio . COLL YTD gains are higher at: -24.795 vs. ORGO (-56.178). COLL has higher annual earnings (EBITDA): 411M vs. ORGO (40.2M). COLL has more cash in the bank: 422M vs. ORGO (91.4M). ORGO has less debt than COLL: ORGO (70.9M) vs COLL (808M). COLL has higher revenues than ORGO: COLL (796M) vs ORGO (513M).
COLLORGOCOLL / ORGO
Capitalization1.13B292M387%
EBITDA411M40.2M1,022%
Gain YTD-24.795-56.17844%
P/E Ratio16.9016.87100%
Revenue796M513M155%
Total Cash422M91.4M462%
Total Debt808M70.9M1,140%
FUNDAMENTALS RATINGS
COLL vs ORGO: Fundamental Ratings
COLL
ORGO
OUTLOOK RATING
1..100
6513
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
46
Fair valued
PROFIT vs RISK RATING
1..100
65100
SMR RATING
1..100
3594
PRICE GROWTH RATING
1..100
5964
P/E GROWTH RATING
1..100
8764
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORGO's Valuation (46) in the Financial Conglomerates industry is in the same range as COLL (48) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew similarly to COLL’s over the last 12 months.

COLL's Profit vs Risk Rating (65) in the Pharmaceuticals Other industry is somewhat better than the same rating for ORGO (100) in the Financial Conglomerates industry. This means that COLL’s stock grew somewhat faster than ORGO’s over the last 12 months.

COLL's SMR Rating (35) in the Pharmaceuticals Other industry is somewhat better than the same rating for ORGO (94) in the Financial Conglomerates industry. This means that COLL’s stock grew somewhat faster than ORGO’s over the last 12 months.

COLL's Price Growth Rating (59) in the Pharmaceuticals Other industry is in the same range as ORGO (64) in the Financial Conglomerates industry. This means that COLL’s stock grew similarly to ORGO’s over the last 12 months.

ORGO's P/E Growth Rating (64) in the Financial Conglomerates industry is in the same range as COLL (87) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew similarly to COLL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COLLORGO
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 6 days ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
69%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
67%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
70%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 20 days ago
69%
N/A
Declines
ODDS (%)
Bearish Trend 1 day ago
67%
Bearish Trend 1 day ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
61%
Bullish Trend 1 day ago
84%
Aroon
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
COLL
Daily Signal:
Gain/Loss:
ORGO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TIQIX36.34N/A
N/A
Touchstone Non-US Equity Y
AZNAX12.19N/A
N/A
Virtus Income & Growth A
CGTRX9.53N/A
N/A
Columbia Select Large Cap Growth Inst2
TMLPX10.68N/A
N/A
Transamerica Energy Infrastructure I
CFNEX101.28-1.34
-1.31%
American Funds Fundamental Invs 529-E

COLL and

Correlation & Price change

A.I.dvisor indicates that over the last year, COLL has been loosely correlated with AMPH. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if COLL jumps, then AMPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COLL
1D Price
Change %
COLL100%
-1.16%
AMPH - COLL
43%
Loosely correlated
+3.04%
AMRX - COLL
40%
Loosely correlated
+1.00%
ANIP - COLL
40%
Loosely correlated
-1.21%
VTRS - COLL
37%
Loosely correlated
+0.74%
EBS - COLL
37%
Loosely correlated
-0.50%
More

ORGO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORGO has been loosely correlated with ANIK. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ORGO jumps, then ANIK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORGO
1D Price
Change %
ORGO100%
-5.42%
ANIK - ORGO
36%
Loosely correlated
+1.09%
PRGO - ORGO
31%
Poorly correlated
-0.49%
AMPH - ORGO
30%
Poorly correlated
+3.04%
ACET - ORGO
29%
Poorly correlated
-3.17%
COLL - ORGO
28%
Poorly correlated
-1.16%
More